Targeted Nanoswitchable Inhibitors of Protein-Protein Interactions Involved in Apoptosis

被引:7
|
作者
Nevola, Laura [1 ]
Varese, Monica [1 ]
Martin-Quiros, Andres [2 ]
Mari, Giacomo [1 ,3 ]
Eckelt, Kay [2 ,4 ]
Gorostiza, Pau [1 ,2 ,4 ,5 ]
Giralt, Ernest [1 ,6 ]
机构
[1] BIST, Inst Res Biomed IRB Barcelona, Baldiri Reixac 10, Barcelona 08028, Spain
[2] Inst Bioengn Catalonia IBEC, Barcelona 08028, Spain
[3] Univ Bologna, I-40126 Bologna, Italy
[4] Network Biomed Res Ctr Bioengn Biomat & Nanomed C, Madrid 28029, Spain
[5] Catalan Inst Res & Adv Studies ICREA, Barcelona 08010, Spain
[6] UB, Barcelona 080280, Spain
关键词
helical structures; optopharmacology; peptide engineering; photoswitchable peptides; protein-protein interactions; PHOTO-CONTROL; CROSS-LINKER; P53; PEPTIDE; CANCER; PHOTOCONTROL; LIMITATIONS; AZOBENZENE;
D O I
10.1002/cmdc.201800647
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Progress in drug delivery is hampered by a lack of efficient strategies to target drugs with high specificity and precise spatiotemporal regulation. The remote control of nanoparticles and drugs with light allows regulation of their action site and dosage. Peptide-based drugs are highly specific, non-immunogenic, and can be designed to cross the plasma membrane. In order to combine target specificity and remote control of drug action, here we describe a versatile strategy based on a generalized template to design nanoswitchable peptides that modulate protein-protein interactions upon light activation. This approach is demonstrated to promote photomodulation of two important targets involved in apoptosis (the interactions Bcl-xL-Bak and MDM2-p53), but can be also applied to a large pool of therapeutically relevant protein-protein interactions mediated by alpha-helical motifs. The template can be adjusted using readily available information about hot spots (residues contributing most to the binding energy) at the protein-protein interface of interest.
引用
收藏
页码:100 / 106
页数:7
相关论文
共 50 条
  • [1] Inhibitors of protein-protein interactions
    Ockey, DA
    Gadek, TR
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (03) : 393 - 400
  • [2] MOTIFS INVOLVED IN PROTEIN-PROTEIN INTERACTIONS
    SLINGSBY, C
    BATEMAN, OA
    SIMPSON, A
    MOLECULAR BIOLOGY REPORTS, 1993, 17 (03) : 185 - 195
  • [3] Protein-protein interactions: Mimics and inhibitors
    Chmielewski, J
    BIOPOLYMERS, 1998, 47 (04) : 263 - 263
  • [4] Peptide Inhibitors of Protein-Protein Interactions
    Friedler, Assaf
    JOURNAL OF PEPTIDE SCIENCE, 2022, 28
  • [5] β-Peptides as inhibitors of protein-protein interactions
    Kritzer, JA
    Stephens, OM
    Guarracino, DA
    Reznik, SK
    Schepartz, A
    BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (01) : 11 - 16
  • [6] Protein-protein interactions and related inhibitors involved in the NLRP3 inflammasome pathway
    Ma, Zhen-yu
    Jiang, Cheng
    Xu, Li-li
    CYTOKINE & GROWTH FACTOR REVIEWS, 2023, 74 : 14 - 28
  • [7] Inhibitors of protein-protein interactions as potential drugs
    Veselovsky, Alexander V.
    Archakov, Alexander I.
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2007, 3 (01) : 51 - 58
  • [8] α-Helix mimetics as inhibitors of protein-protein interactions
    Saraogi, Ishu
    Hamilton, Andrew D.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2008, 36 : 1414 - 1417
  • [9] Inhibitors of protein-protein interactions: Helix mimetics
    Feng, Jianwen
    Marshall, Garland
    BIOPHYSICAL JOURNAL, 2007, : 204A - 204A
  • [10] Computational identification of inhibitors of protein-protein interactions
    Zhong, Shijun
    Macias, Alba T.
    MacKerell, Alexander D., Jr.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (01) : 63 - 82